Tremor Gram – July 2019

Developing a Drug to Mimic the Effects of Alcohol on ET

The IETF has awarded a 2019 research grant to Dr. Adrian Handforth with the Veterans Affairs Greater Los Angeles Healthcare System. The grant will support a research project titled, “Evaluation of an a6βy2 GABA Receptor-Specific Drug as Potential Therapy.”

This research will explore the potential of developing a drug that mimics how low doses of alcohol can suppress the effects of tremor, but with more selectivity of molecular targets to try to avoid adverse effects found with other medications used for management of essential tremor.

Each year, the IETF awards research grants to projects that address the nosology, etiology, pathogenesis and other topics relevant to essential tremor. Thanks to the generosity of the ET community, the IETF has awarded over $800,000 to date in research grants.

You can help shine a light on ET with your special gift during the 2019 IETF Research Campaign in July.

Watch your mailbox for a special letter with our “Shine a Light” logo. It will include a donation response card that will allow you to get involved in supporting essential tremor research. Or make a donation online to keep the light of hope shining strong.


Wrist-Worn Device to Treat ET Coming in the Fall

Cala Health has announced the release of its Cala Trio wrist-worn therapy device for people with essential tremor.

Cala Trio Promotional Art 2019Many individuals connected with the International Essential Tremor Foundation took part in nationwide clinical trials for the Cala Trio during the past two years. The device, which looks like a smart watch, delivers electrical stimulation to the nerves in the wrist. Results showed “75 percent of patients experienced temporary meaningful symptom improvement after a single 40-minute stimulation session” according to the Cala Trio website.

Cala Trio will be available in the fall of 2019 in select U.S. markets. For more information visit the Cala Trio website.

Cannabis Remains a Medical Mystery

Medical marijuana (or cannabis) continues to be a hot topic in the U.S. It’s a legal substance in more than half of U.S. states, yet the medical impact it has is still a mystery. Why is this?

Dr. Fatta Nahab, a member of the International Essential Tremor Foundation’s medical advisory board, took part in a video that addresses this topic.

Cannabidiol clip artAs it has become easier for individuals to buy cannabis, it has become harder for scientists to study it, according to the video,”Weed is Everywhere, So Why is it Still a Medical Mystery?

A neurologist at the University of California San Diego Health and associate professor of neurosciences, Dr. Nahab is overseeing a clinical trial to examine the safety, efficacy and pharmacological properties of cannabis to treat ET in adults. The IETF provided a research grant to help fund this study.

Cannabis is still a Schedule I drug in the U.S. meaning it has no medicinal value. So if physicians in the U.S. want to study it, they have to undergo a complicated regulation process.

So much research is yet to be conducted on the role of cannabis in brain development, cognition and regulating mood.

This video gives an overview of the complications of studying cannabis by U.S. scientists.